New medicines for lasting change

We’re tackling the world’s most challenging diseases so that communities can thrive around the world

FEATURED

2020 Annual Report

MDGH celebrated its 15th anniversary in 2020. Our 2020 Annual Report documents our progress as well as our current thinking on our contribution to neglected disease R&D and access to medicines.

WHAT WE DO

We develop new and improved medicines for neglected diseases

Medicines Development for Global Health (MDGH) develops new medicines for people and communities who are disadvantaged by the traditional consideration of market returns.

In 2018, we became the first solo not-for-profit company to achieve FDA approval for a novel medicine, when we registered moxidectin, the first new treatment for river blindness (onchocerciasis) in 20 years. Supported by our collaborators, we are working towards making a lasting change in the lives of people affected by neglected diseases.

HOW WE WORK

We have a unique approach

Addressing the gap

Of the approximately 400 New Drug Applications (NDAs) approved in the years 2009 to 2020, only 10 were for neglected infectious diseases, which affect more than a billion people globally. As a social enterprise, we take an innovative approach to developing new and improved treatments for neglected diseases, helping to elevate the health status of affected communities in low- and middle-income countries.

Developing medicines

We are addressing important and unmet medical needs in global health through the development and delivery of new medicines. Our development model is resource-efficient and cost-effective, and built on identifying and integrating the necessary expertise from each part of the development pathway at the time that expertise is needed.

WORKING Collaboratively

We work constructively to address global health inequities, but our work is just one piece of a larger puzzle. Our team relies on strong collaboration networks and continuously seeks fruitful and effective partnerships to increase our chances of reducing the burden of neglected diseases.

NEGLECTED DISEASES

We’re working to find lasting solutions for these diseases

Tuberculosis

Primarily affecting the lungs, tuberculosis remains the leading cause of infectious death worldwide.

More about this disease

Strongyloidiasis

A soil-transmitted infection affecting up to 100 million people, particularly children.

More about this disease

Soil-transmitted helminth infections

Among the most common of all infections with an estimated 1.5 billion people infected worldwide.

More about this disease

Scabies

An infectious skin condition affecting more than 200 million people at any one time.

More about this disease

River blindness

A debilitating and disfiguring disease found in 31 African countries and beyond.

More about this disease

Lymphatic filariasis

A painful and debilitating disease of the lymph system affecting over 50 million people at any one time.

More about this disease

Leprosy

A chronic infectious disease which may cause skin lesions and nerve damage found in 127 countries.

More about this disease
Where we work

MDGH consists of independent legal entities in the following countries which collaborate in pursuance of their mission

YOU ARE HERE
22 Dec 2020

Headquarters, Australia

Medicines Development for Global Health Limited is an independent biopharmaceutical company incorporated in Australia (Australian Company Number 116 977 523) and registered as a charity with the Australian Charities and Not-for-profits Commission. Any donation made through this website will go towards the work of MDGH Australia. Donations made to the United Kingdom or United States affiliate offices fund the work of that entity.

United Kingdom

Medicines Development for Global Health Limited was incorporated on 3 June 2015 as a company limited by guarantee in the UK. Its application for registration with the Charity Commission for England and Wales is underway.

Visit UK website

United States

Medicines Development for Global Health Inc. was incorporated on 6 July 2021 as a non-profit corporation. It is in the process of applying for registration as a tax-exempt 501(c)(3) public charity.

Visit US website
Very few things we do are as impactful as the development of a medicine to treat or prevent a disease.
—Mark Sullivan, Founder and Managing Director